Regeneron Pharmaceuticals Inc. (REGN) Pops 3.21% for February 15

Equities Staff |

One of the S&P 500’s big winners for Monday February 15 was Regeneron Pharmaceuticals Inc. (REGN) as the company’s stock climbed 3.21% to $379.01 on volume of 728,165 shares.

The stock opened at $371.36 and saw an intraday low of $365.13 and an intraday high of $379.04. All told, the day saw a per-share gain of $11.77. The stock’s average daily volume of 871,062 and 104.07 million shares outstanding. Regeneron Pharmaceuticals Inc. now has a 50-day SMA is $486.52 and 200-day SMA is $517.77, and it has a 52-week high of $605.93 and a 52-week low of $350.26.

Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Based out of Tarrytown, NY, Regeneron Pharmaceuticals Inc. has 2,925 employees and, after today’s trading, reached a market cap of $39.44 billion. The stock’s P/E Ratio is 66.6. Its P/S ratio is 9.31, P/B ratio is 11.96, and P/FCF ratio is 69.6.

For a complete fundamental analysis analysis of Regeneron Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for REGN. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…

Almond Smart Home Router by Securifi

Securifi sells user friendly touch screen routers that also have support for IoT/home automation.Securifi’s Almond revolutionized wireless router setup with its easy to use Touchscreen Interface in 2012. Now our…